Agios' Pivot to Late-Stage Projects Results in Loss of 50 Jobs
Agios Pharmaceuticals is cutting its staff numbers by 50 as part of plans to lay low on exploratory research efforts to focus on the success of late-stage initiatives.
The Home of the Life Sciences Industry
Seagen CEO Resigns Following Domestic Violence Allegations
Clay Siegall resigned his role as president, CEO and a member of the board of directors of Seagen following domestic violence allegations. Roger Dansey will serve as interim CEO.
More Top Stories
- Exciting Advancements in Multiple Myeloma, Asthma and Alzheimer’s
- AbbVie, AstraZeneca See Value in what Cugene, Proteros Have to Offer
- Sofinnova Nets $1B+ from Apollo to Accelerate Biotech Growth
- Will Proposed COVID-19 TRIPS Waiver Help Patients or Harm Innovation?
- Researchers Pinpoint Important Biomarker for SIDS - Updated
